Inclusion Criteria:

- Histologically or cytologically confirmed evidence of metastatic/ unresectable
uveal melanoma

- Measurable disease, defined as at least one lesion that can be accurately measured in
at least one dimension and is ≥10 mm by spiral CT scan

- 18 years or older

- Eastern Cooperative Oncology Group(ECOG)performance status 0, or 1

- No known HIV or Hepatitis B or C

- Patients with brain metastasis are eligible for entry into the study

- Patients must have normal organ/marrow function as defined below:

- Absolute neutrophil count ≥ 1.5 x 109/L

- Platelets ≥ 100,000 x 109/L

- Hemoglobin ≥ 9.0 gm/100 ml

- Total bilirubin ≤ 1.5. In patients with Gilbert's disease the indirect bilirubin
must be less than or equal to 4.0.

- AST and ALT ≤ 2.5x upper limit of normal

- Alkaline phosphatase ≤ 2.5x upper limit of normal, unless bone metastases is
present in the absence of liver metastasis

- Creatinine ≤ 1.8 mg/ml or calculated creatinine clearance > 50 mg ml.

- Calcium <12 mg/dl when corrected for levels of serum albumen

- Patients my have had up to one prior systemic therapy

Exclusion Criteria:

- Chemotherapy or radiotherapy within 4 weeks prior to entering the study or failure to
recover from adverse events due to agents administered more than 4 weeks earlier.

- May not be receiving any other simultaneous investigational agents

- No prior malignancy except for adequately treated basal cell cancer, in situ cervical
cancer or other cancer for which the patient has been disease free for 2 years.

- Patients who have serious infections or other major uncontrolled medical illnesses.

- Patients who have significant psychiatric illness who in the opinion of the principal
investigator would prevent adequate informed consent or render therapy unsafe.

- Patients who are pregnant. Female patients of child bearing potential must have a
negative serum pregnancy test and use adequate contraception protection while on
study.

- Peripheral neuropathy of > grade 2.